Core Viewpoint - Luyuan Pharmaceutical (002788) has announced a three-year shareholder return plan for 2025-2027, prioritizing cash dividends and establishing a differentiated cash dividend policy based on various factors [1] Group 1: Shareholder Return Plan - The company will prioritize cash distribution for dividends and will allocate a certain percentage of the distributable profits to shareholders annually, contingent on meeting dividend conditions [1] - The minimum proportion of cash dividends in the profit distribution will be set at 20% [1] - The board will consider industry characteristics, development stage, operational model, profitability, debt repayment capacity, significant capital expenditure plans, and investor returns when proposing the cash dividend policy [1]

会议资料 二○二五年五月 山鹰国际 600567 2024 年年度股东会会议资料 山鹰国际 600567 2024 年年度股东会会议资料 山鹰国际控股股份公司 目 录 议案六、关于确认公司董事 2024 年度薪酬发放情况及 2025 年度薪酬 议案七、关于确认公司监事 2024 年度薪酬发放情况及 2025 年度薪酬 议案九、关于 2025 年度向金融机构申请综合授信额度的议案 ... 33 议案十一、关于公司及控股子公司提供资产抵押的议案 ........ 38 议案十二、关于公司及控股子公司开展金融衍生品投资业务的议案 第 2页 共 46 页 山鹰国际 600567 2024 年年度股东会会议资料 议案十三、关于制定《山鹰国际控股股份公司未来三年 （2025-2027） 第 3 页 共 46 页 山鹰国际 600567 2024 年年度股东会会议资料 会议议程 会议时间：2025 年 5 月 21 日 14:30 会议方式：现场投票和网络投票相结合 现场会议地点：安徽省马鞍山市勤俭路山鹰国际办公大楼 会议主持人：吴明武先生 一、主持人宣布会议开始，公布参加股东会股东人数及所代表的 有表决权股份数； 二、会 ...

Core Viewpoint - The company, Hao Xiang Ni, reported a revenue of 1.67 billion yuan in 2024, a year-on-year decrease of 3.39%, and a net profit attributable to shareholders of -72 million yuan, a decline of 38.67%, marking three consecutive years of losses [1] Group 1: Financial Performance - In 2024, the company achieved a revenue of 1.67 billion yuan, down 3.39% year-on-year [1] - The net profit attributable to shareholders was -72 million yuan, representing a 38.67% decline compared to the previous year [1] - Cumulatively, the company has incurred losses exceeding 300 million yuan over the past three years, with net profits of -189 million yuan in 2021 and -52 million yuan in 2022 [1] Group 2: Dividend Policy - Despite consecutive losses, the company plans to distribute a cash dividend of 10 yuan per 10 shares, totaling approximately 432 million yuan for the 2024 fiscal year, along with an additional 173 million yuan in mid-year dividends, bringing the total to 605 million yuan [2] - The company's management stated that the dividend policy considers both investor demands and sustainable business operations, aiming to enhance shareholder returns and confidence [3] Group 3: Shareholding Structure - Approximately 30% of the high dividends are allocated to the founder's family, with the chairman holding 28.59% of the shares, and other family members holding a combined total of over 31% [4] - The chairman, Shi Jubin, and his family members are identified as acting in concert, indicating a significant influence over the company's decisions [4]

根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司证券 发行注册管理办法》等有关法律、法规及规范性文件的规定，经过对公司实际情 况及相关事项进行自查和论证，监事会认为公司各项条件符合现行法律、法规和 规范性文件中关于上市公司向特定对象发行股票的有关规定，具备本次向特定对 象发行股票的资格和条件。 证券代码：300266 证券简称：兴源环境 公告编号：2025-039 兴源环境科技股份有限公司 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 兴源环境科技股份有限公司（以下简称"公司"）第六届监事会第四次会议 于2025年5月12日以通讯方式召开。会议通知已经于2025年5月9日以电子邮件方 式送达全体监事。本次会议应出席监事3人，实际出席监事3人。本次会议的通知、 召开以及参会监事人数均符合相关法律、法规、规则及《公司章程》的有关规定。 本次会议形成以下决议： 一、审议通过《关于公司符合向特定对象发行股票条件的议案》 本议案尚需提交公司股东大会审议。 表决结果：同意3票，反对0票，弃权0票。 二、逐项审议通过《关于公司2025年度向特定对象发行A股股 ...

Core Viewpoint - Zhejiang Sitaili Pharmaceutical Co., Ltd. is preparing for its shareholder meeting scheduled for May 22, 2025, focusing on maintaining shareholder rights and ensuring orderly proceedings during the meeting [1][2]. Meeting Arrangements - The meeting will be held on May 22, 2025, at 14:30, with online voting available from 9:15 to 11:30 and 13:00 to 15:00 on the same day [3]. - The venue for the meeting is located at No. 9, Fengxi West Road, Modern Industrial Gathering Area, Xianju County, Zhejiang Province [3]. Shareholder Rights and Meeting Conduct - Shareholders have the right to speak, inquire, and vote, but must apply to the meeting's organizing committee to do so [2]. - The voting will be conducted via a named ballot, with each share granting one vote, and any improperly filled ballots will be considered as abstentions [2][3]. Board of Directors and Governance - The fifth board of directors consists of 7 members, including 3 independent directors, and has held 8 meetings during the reporting period to discuss various corporate matters [6]. - The board has focused on maintaining good governance and protecting shareholder interests through active discussions and independent opinions [6]. Financial Performance Overview - The company reported a steady growth in operating performance for 2024, with total assets reaching approximately 6.05 billion yuan, an increase of 9.59% compared to the previous year [15]. - The financial report indicates a decrease in cash and cash equivalents by 14.47% and a decline in accounts receivable by 10.76% [14][15]. Future Outlook - The company anticipates challenges in 2025 due to external factors such as safety and environmental risks, as well as increased competition in the industry [9]. - The board will closely monitor changes in external policies and economic conditions to provide strategic recommendations for sustainable development [9].

Meeting Information - The annual shareholders' meeting of Zhejiang Aoxiang Pharmaceutical Co., Ltd. is scheduled for May 20, 2025, at 14:00 [1] - The meeting will be held at the company's new office building in Linhai, Zhejiang [1] - Voting will be conducted through both on-site and online platforms [3] Shareholder Rights and Responsibilities - Shareholders must present identification and relevant documents to attend the meeting [2] - Shareholders have the right to speak, inquire, and vote during the meeting [2] - The meeting will follow a structured agenda, including the reading of proposals and voting on resolutions [2][3] Financial Performance - In 2024, the company reported a revenue of approximately RMB 795.29 million, a decrease of 2.63% from 2023 [18] - The net profit attributable to shareholders was approximately RMB 206.79 million, down 18.55% year-on-year [18] - The company's total assets increased by 1.04% to approximately RMB 2.98 billion, while net assets rose by 6.08% to approximately RMB 2.27 billion [18] Board of Directors' Report - The board emphasized a commitment to responsible governance and strategic decision-making to enhance shareholder value [4][6] - The board has established specialized committees to oversee various aspects of company operations, including audit and remuneration [6][7] Future Development Strategy - The company aims to leverage its R&D capabilities to capture opportunities in the global pharmaceutical market, particularly as many innovative drug patents expire [8] - The focus will be on developing high-value products and expanding into international markets [8][9] - The company plans to enhance its marketing strategies and strengthen customer relationships to ensure long-term growth [9] Profit Distribution Proposal - The board proposed a cash dividend of RMB 1 per 10 shares, totaling approximately RMB 82.83 million, which represents 40.05% of the net profit for 2024 [21]

Investment Rating - The investment rating for Rongsheng Petrochemical is "Buy" [1] Core Views - The company's performance has shown significant marginal improvement, and shareholder returns have enhanced its long-term investment value [1] - The report highlights that the refining and chemical industry is currently in a weak cycle, which may put short-term pressure on the company's performance [4] - The first quarter of 2025 saw a substantial improvement in the company's performance, indicating potential for profit elasticity [4][5] - The company has established a three-year shareholder return plan, emphasizing its long-term investment value [7] Financial Performance Summary - In 2024, the company achieved operating revenue of 326.475 billion yuan, a year-on-year increase of 0.42%, while net profit attributable to shareholders was 724 million yuan, a decrease of 37.44% [1] - The first quarter of 2025 reported operating revenue of 74.975 billion yuan, a year-on-year decrease of 7.54%, but net profit attributable to shareholders increased by 6.53% year-on-year [2] - The forecast for 2025-2027 indicates a significant recovery in net profit, with expected figures of 2.356 billion yuan, 2.783 billion yuan, and 3.935 billion yuan respectively, reflecting growth rates of 225.2%, 18.1%, and 41.4% [7] Industry Insights - The refining industry is entering a phase of stock competition, with a focus on "strong alliances" to create new development opportunities [4] - The average Brent crude oil price for 2024 is projected to be 79.86 USD/barrel, indicating a slight decrease from the previous year [4] - The report notes that the company is collaborating with Saudi Aramco, which is expected to enhance its global market presence and operational resilience [5]

2024年中喜会计师事务所购买的职业保险累计赔偿限额10,000.00万元，能够覆盖因审计失败导致的民事 赔偿责任。 登录新浪财经APP 搜索【信披】查看更多考评等级 3、诚信记录 中喜所未受到刑事处罚。 中喜所近三年执业行为受到监督管理措施5次，21名从业人员近三年因执业行为受到监督管理措施共11 次。 中喜所近三年执业行为受到行政处罚1次，2名从业人员近三年因执业行为受到行政处罚共1次。 中喜所近三年执业行为受到纪律处分1次，2名从业人员近三年因执业行为受到纪律处分共1次。 （二）项目信息 1、中喜会计师事务所（特殊普通合伙）及其从业人员不存在违反《中国注册会计师职业道德守则》对 独立性要求的情形。项目组成员具备相应的专业胜任能力，主要成员信息如下： （1）项目合伙人：蒋建友，中国注册会计师，2002年注册，长期从事审计及与资本市场相关的专业服 务工作，具备相应专业胜任能力。 （2）拟任签字注册会计师：欧阳静波，中国注册会计师，2009年注册，长期从事审计及与资本市场相 关的专业服务工作，具备相应的专业胜任能力。 （3）项目质量控制复核人：黄颖君，中国注册会计师，2009年注册，长期从事审计及与资本市场相 ...

证券代码：300939 证券简称：秋田微 深圳秋田微电子股份有限公司 投资者关系活动记录表 | 024-047）。后续如有股权激励计划，将严格按照相关规定及时履行信 | 息披露义务，敬请关注公司后续披露的相关公告。谢谢！ | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 2.请问截止到 | 月 | 日收盘，公司股东人数是多少？ | 4 | 29 | | | | | 答：尊敬的投资者，您好！根据中国证券登记结算有限责任公司下发 | 的《合并普通账户和融资融券信用账户前 | 名明细数据表》显示，截 | N | | | | | | 至 | 年 | 月 | 日，公司股份持有人数（已合并）为 | 14,951。谢谢！ | 2025 | 04 | 18 | | 3.请问，自公司上市以来多年分红，后续的分红规划是什么？ | | | | | | | | | 答：尊敬的投资者，您好！公司于 | 年 | 月 | 日披露了《未来三 | 2023 | 04 | 20 | 年（2023-2025）股东回报规划》。公司实行持续、稳定的利润分配政 | | 策 ...

Investment Rating - The report maintains a "Recommended" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [7][8]. Core Views - The company reported a revenue of 31.196 billion yuan and a net profit of 13.473 billion yuan for 2024, reflecting year-on-year growth of 3.19% and 1.71% respectively. The fourth quarter of 2024 saw a decline in revenue and net profit, with year-on-year decreases of 16.86% and 29.86% respectively [3]. - The company adheres to a "dual brand, three product lines, and major products" strategy, with a focus on high-end liquor. The revenue from liquor operations reached 31.053 billion yuan, with a gross margin of 87.62%, showing a slight decline [4]. - The company has committed to a shareholder return plan, ensuring that cash dividends will account for at least 65% of net profit for 2024, 70% for 2025, and 75% for 2026, with a minimum total of 8.5 billion yuan in cash dividends each year [6][8]. Summary by Sections Financial Performance - For 2024, the company achieved a total revenue of 31.196 billion yuan, with a net profit of 13.473 billion yuan. The expected revenue for 2025 is projected at 31.883 billion yuan, with a net profit of 13.753 billion yuan, indicating a growth rate of 2.2% [9][10]. - The gross margin for 2024 was reported at 87.54%, with a slight decline expected in the following years [11]. Revenue Breakdown - The high-end liquor segment generated 27.585 billion yuan in revenue, while other liquor products contributed 3.467 billion yuan. The high-end segment saw a volume increase of 14.39% but a price decrease of 10.15% [4]. - The company’s revenue from traditional and emerging channels was 29.573 billion yuan and 1.479 billion yuan respectively, showing growth in both areas [4]. Shareholder Returns - The company plans to distribute a total cash dividend of 6.8 billion yuan for 2024, alongside a previously implemented 2 billion yuan interim dividend, meeting the 65% payout ratio requirement [8]. - The projected dividend yield for 2024 is 4.75%, reflecting the company's commitment to returning value to shareholders [6][8].